Heron Therapeutics is trading at $0.31, down 7.62%, with broad market weakness the likeliest explanation; no source directly attributes the move to it. - No new company announcement was listed for October 22; the latest investor-relations release shown is from August 10. - Supplied market context shows the S&P 500 and Nasdaq down more than 0.5% amid geopolitical tensions and rising oil prices. - The withdrawal of 2026 guidance and uncertainty around CINVANTI are older context, not fresh catalysts for October 22.